Intarcia, the maker of a subdermal pump for once-a-year diabetes drug delivery, added optimized peptides to its arsenal via the acquisition of the Research Triangle's Phoundry Pharmaceuticals. It's ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results